Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had its price target decreased by Jefferies Group from $86.00 to $58.00 in a report published on Thursday. Jefferies Group currently has a buy rating on the biopharmaceutical company’s stock.
A number of other brokerages have also recently commented on ALNY. Leerink Swann reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, July 19th. Needham & Company LLC cut Alnylam Pharmaceuticals to a buy rating and dropped their price target for the company from $152.00 to $137.00 in a research report on Thursday, October 6th. JMP Securities reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, July 10th. Janney Montgomery Scott initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, September 28th. They set a neutral rating and a $74.00 price target on the stock. Finally, Credit Suisse Group AG reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $80.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 35.52 on Thursday. Alnylam Pharmaceuticals has a 12 month low of $33.16 and a 12 month high of $110.75. The company has a 50 day moving average price of $69.62 and a 200-day moving average price of $65.95. The company’s market cap is $3.04 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The business had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.09 million. During the same quarter in the previous year, the firm earned ($0.85) earnings per share. The business’s revenue was up .2% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current fiscal year.
In other news, CEO John Maraganore sold 30,151 shares of the stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the transaction, the chief executive officer now directly owns 148,465 shares in the company, valued at approximately $9,604,200.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.00% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $128,000. Seven Eight Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,800 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $175,000. Bank of Montreal Can bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $193,000. Finally, BlueMountain Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 1,500 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.